Literature DB >> 11233414

Cancer research. Anti-inflammatories inhibit cancer growth--but how?

J Marx.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11233414     DOI： 10.1126/science.291.5504.581

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  13 in total

1.  Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

Authors:  Driss Ait Ouakrim; Seyedeh Ghazaleh Dashti; Rowena Chau; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Barbara Leggett; Finlay A Macrae; Dennis J Ahnen; Graham Casey; Steven Gallinger; Robert W Haile; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  J Natl Cancer Inst       Date:  2015-06-24       Impact factor: 13.506

2.  Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.

Authors:  D A Dixon; N D Tolley; P H King; L B Nabors; T M McIntyre; G A Zimmerman; S M Prescott
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  Diverse amide analogs of sulindac for cancer treatment and prevention.

Authors:  Bini Mathew; Judith V Hobrath; Michele C Connelly; R Kiplin Guy; Robert C Reynolds
Journal:  Bioorg Med Chem Lett       Date:  2017-09-13       Impact factor: 2.823

4.  Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective Cox-2 inhibitor.

Authors:  Bhupesh Parashar; Sai Latha Shankar; Kathleen O'Guin; James Butler; Bhadrasain Vikram; Bridget Shafit-Zagardo
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

5.  TGF-β1 mediates the effects of aspirin on colonic tumor cell proliferation and apoptosis.

Authors:  Yuyi Wang; Chi Du; Nan Zhang; Mei Li; Yanyang Liu; Maoyuan Zhao; Feng Wang; Feng Luo
Journal:  Oncol Lett       Date:  2018-02-14       Impact factor: 2.967

6.  The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks.

Authors:  Amy J Johnson; Ao-Lin Hsu; Ho-Pi Lin; Xueqin Song; Ching-Shih Chen
Journal:  Biochem J       Date:  2002-09-15       Impact factor: 3.857

7.  Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398.

Authors:  Xiao-Chun Xu; Scott B Shappell; Zhengdong Liang; Shumei Song; David Menter; Vemparala Subbarayan; Sunita Iyengar; Dean G Tang; Scott M Lippman
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

8.  Rofecoxib reduces polyp recurrence in familial polyposis.

Authors:  A Hallak; L Alon-Baron; R Shamir; M Moshkowitz; B Bulvik; E Brazowski; Z Halpern; N Arber
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

9.  Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29).

Authors:  M Gallicchio; A C Rosa; C Dianzani; L Brucato; E Benetti; M Collino; R Fantozzi
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

10.  Nanoprodrugs of NSAIDs: Preparation and Characterization of Flufenamic Acid Nanoprodrugs.

Authors:  Bong-Seop Lee; Chi Woo Yoon; Arsen Osipov; Nuriel Moghavem; Daniel Nwachokor; Rina Amatya; Rebekah Na; Joe L Pantoja; Michael D Pham; Keith L Black; John S Yu
Journal:  J Drug Deliv       Date:  2011-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.